Phosphorylation of tau protein at sites Ser396-404 is one of the earliest events in Alzheimer's disease and Down syndrome

Neuropathology and Applied Neurobiology

Volumn 40, Issue 2, 2014, Pages 121-135

  Mondragon Rodriguez S ^a   Perry, G ^c,d   Luna Munoz J ^e   Acevedo Aquino, M C ^b   Williams, S ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Alzheimer disease; Cleavage; Down syndrome; Early event; Phosphorylation; Tau

Indexed keywords

TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; DOWN SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION;

ALZHEIMER DISEASE; CLEAVAGE; DOWN SYNDROME; EARLY EVENT; PHOSPHORYLATION; TAU;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; DISEASE PROGRESSION; DOWN SYNDROME; HUMANS; MIDDLE AGED; NEUROFIBRILLARY TANGLES; PHOSPHORYLATION; TAU PROTEINS;

EID: 84892419941     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/nan.12084     Document Type: Article

References (38)

1. Pickhardt M, Gazova Z, von Bergen M, Khlistunova I, Wang Y, Hascher A, Mandelkow EM, Biernat J, Mandelkow E. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J Biol Chem 2005; 280: 3628-3635
2. Mondragon-Rodriguez S, Perry G, Zhu X, Boehm J. Amyloid Beta and tau proteins as therapeutic targets for Alzheimer's disease treatment: rethinking the current strategy. Int J Alzheimers Dis 2012; 2012: 630182
3. Gravitz L. Drugs: a tangled web of targets. Nature 2011; 475: S9-11
4. Mondragon-Rodriguez S, Basurto-Islas G, Lee HG, Perry G, Zhu X, Castellani RJ, Smith MA. Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis. Expert Rev Neurother 2010; 10: 683-691
5. Nelson LD, Siddarth P, Kepe V, Scheibel KE, Huang SC, Barrio JR, Small GW. Positron emission tomography of brain beta-amyloid and tau levels in adults with Down syndrome. Arch Neurol 2011; 68: 768-774
6. Wilson RS, Segawa E, Boyle PA, Anagnos SE, Hizel LP, Bennett DA. The natural history of cognitive decline in Alzheimer's disease. Psychol Aging 2012; 27: 1008-1017
7. Lai F, Williams RS. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol 1989; 46: 849-853
8. Mondragon-Rodriguez S, Basurto-Islas G, Santa-Maria I, Mena R, Binder LI, Avila J, Smith MA, Perry G, Garcia-Sierra F. Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease. Int J Exp Pathol 2008; 89: 81-90
9. Ledesma MD, Avila J, Correas I. Isolation of a phosphorylated soluble tau fraction from Alzheimer's disease brain. Neurobiol Aging 1995; 16: 515-522
10. Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B, Liu F, Rahman A, Tanimukai H, Grundke-Iqbal I. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005; 1739: 198-210
11. Skrabana R, Kontsek P, Mederlyova A, Iqbal K, Novak M. Folding of Alzheimer's core PHF subunit revealed by monoclonal antibody 423. FEBS Lett 2004; 568: 178-182
12. Wang J, Wang X, Liu R, Wang Q, Grundke-Iqbal I, Iqbal K. In vitro analysis of tau phosphorylation sites and its biological activity. Chin Med Sci J 2002; 17: 13-16
13. Hu YY, He SS, Wang XC, Duan QH, Khatoon S, Iqbal K, Grundke-Iqbal I, Wang JZ. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett 2002; 320: 156-160
14. Carmel G, Mager EM, Binder LI, Kuret J. The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology. J Biol Chem 1996; 271: 32789-32795
15. Novak M. Truncated tau protein as a new marker for Alzheimer's disease. Acta Virol 1994; 38: 173-189
16. Fasulo L, Ugolini G, Visintin M, Bradbury A, Brancolini C, Verzillo V, Novak M, Cattaneo A. The neuronal microtubule-associated protein tau is a substrate for caspase-3 and an effector of apoptosis. J Neurochem 2000; 75: 624-633
17. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A 2003; 100: 10032-10037
18. Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW. Tau, tangles, and Alzheimer's disease. Biochim Biophys Acta 2005; 1739: 216-223
19. Pevalova M, Filipcik P, Novak M, Avila J, Iqbal K. Post-translational modifications of tau protein. Bratisl Lek Listy 2006; 107: 346-353
20. Guillozet-Bongaarts AL, Garcia-Sierra F, Reynolds MR, Horowitz PM, Fu Y, Wang T, Cahill ME, Bigio EH, Berry RW, Binder LI. Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol Aging 2005; 26: 1015-1022
21. Luna-Munoz J, Chavez-Macias L, Garcia-Sierra F, Mena R. Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease. J Alzheimers Dis 2007; 12: 365-375
22. Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, LaFerla FM, Rohn TT, Cotman CW. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 2004; 114: 121-130
23. Mena R, Edwards PC, Harrington CR, Mukaetova-Ladinska EB, Wischik CM. Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease. Acta Neuropathol (Berl) 1996; 91: 633-641
24. Garcia-Sierra F, Ghoshal N, Quinn B, Berry RW, Binder LI. Conformational changes and truncation of tau protein during tangle evolution in Alzheimer's disease. J Alzheimers Dis 2003; 5: 65-77
25. Mena R, Wischik CM, Novak M, Milstein C, Cuello AC. A progressive deposition of paired helical filaments (PHF) in the brain characterizes the evolution of dementia in Alzheimer's disease. An immunocytochemical study with a monoclonal antibody against the PHF core. J Neuropathol Exp Neurol 1991; 50: 474-490
26. Sahara N, Deture M, Ren Y, Ebrahim AS, Kang D, Knight J, Volbracht C, Pedersen JT, Dickson DW, Yen SH, Lewis J. Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain. J Alzheimers Dis 2012; 33: 249-263
27. Nuebling GS, Bader B, Levin J, Hildebrandt J, Kretzschmar H, Giese A. Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with alpha-synuclein at the single molecule level. Mol Neurodegener 2012; 7: 35
28. Lee HG, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, Takeda A, Nunomura A, Smith MA. Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol Med 2005; 11: 164-169
29. Mondragon-Rodriguez S, Trillaud-Doppia E, Dudilot A, Bourgeois C, Lauzon M, Leclerc N, Boehm J. Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation. J Biol Chem 2012; 287: 32040-32053
30. Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 2009; 15: 112-119
31. Mondragón-Rodríguez S, Basurto-Islas G, Binder LI, García-Sierra F. Conformational changes and cleavage; are these responsible for the tau aggregation in Alzheimer's disease? Future Neurol 2009; 4: 39-53. doi:10.2217/14796708.4.1.39
32. Mondragon-Rodriguez S, Mena R, Binder LI, Smith MA, Perry G, Garcia-Sierra F. Conformational changes and cleavage of tau in Pick bodies parallel the early processing of tau found in Alzheimer pathology. Neuropathol ApplNeurobiol 2008; 34: 62-75
33. Garcia-Sierra F, Hauw JJ, Duyckaerts C, Wischik CM, Luna-Munoz J, Mena R. The extent of neurofibrillary pathology in perforant pathway neurons is the key determinant of dementia in the very old. Acta Neuropathol (Berl) 2000; 100: 29-35
34. Luna-Munoz J, Peralta-Ramirez J, Chavez-Macias L, Harrington CR, Wischik CM, Mena R. Thiazin red as a neuropathological tool for the rapid diagnosis of Alzheimer's disease in tissue imprints. Acta Neuropathol (Berl) 2008; 116: 507-515
35. Galvan M, David JP, Delacourte A, Luna J, Mena R. Sequence of neurofibrillary changes in aging and Alzheimer's disease: a confocal study with phospho-tau antibody, AD2. J Alzheimers Dis 2001; 3: 417-425
36. Otvos L Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 1994; 39: 669-673
37. Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 1993; 10: 1089-1099
38. Novak M, Kabat J, Wischik CM. Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. EMBO J 1993; 12: 365-370